Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl M Gay

Showing results (31-40 of 80) with videos related to

Pageof 8
Sort By:
Cancer Research|December 18, 2025
Small Cell Lung Cancer Classification: Unraveling Heterogeneity to Enable Personalized TreatmentsKristiina Boettiger, Ildikó Kovács, Lilla Horvath, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 31, 2019
Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLCTriparna Sen, Carminia M Della Corte, Snezana Milutinovic, et al.
Molecular Cancer|December 2, 2025
Multi-omic profiling provides insights into the heterogeneity, microenvironmental features, and biomarker landscape of small-cell lung cancerMingchao Xie, Miljenka Vuko, Shashank Saran, et al.
JAMA Network Open|June 6, 2022
Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative DurvalumabYufei Liu, Zhe Zhang, Waree Rinsurongkawong, et al.
Molecular Cancer Research : MCR|November 11, 2020
AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR InhibitorsKavya Ramkumar, C Allison Stewart, Kasey R Cargill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2021
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized StudyLauren Averett Byers, Dmitry Bentsion, Steven Gans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2021
Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung CancerYing Jin, Yamei Chen, Huarong Tang, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 29, 2022
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trialCarminia Maria Della Corte, Morena Fasano, Vincenza Ciaramella, et al.
Molecular Cancer|May 29, 2024
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 studyMingchao Xie, Miljenka Vuko, Jaime Rodriguez-Canales, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2020
Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLCOlsi Gjyshi, Ting Xu, Adnan Elhammali, et al.
Pageof 8

Showing results (31-40 of 80) with videos related to

Sort By:
Pageof 8
Cancer Research|December 18, 2025
Small Cell Lung Cancer Classification: Unraveling Heterogeneity to Enable Personalized TreatmentsKristiina Boettiger, Ildikó Kovács, Lilla Horvath, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 31, 2019
Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLCTriparna Sen, Carminia M Della Corte, Snezana Milutinovic, et al.
Molecular Cancer|December 2, 2025
Multi-omic profiling provides insights into the heterogeneity, microenvironmental features, and biomarker landscape of small-cell lung cancerMingchao Xie, Miljenka Vuko, Shashank Saran, et al.
JAMA Network Open|June 6, 2022
Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative DurvalumabYufei Liu, Zhe Zhang, Waree Rinsurongkawong, et al.
Molecular Cancer Research : MCR|November 11, 2020
AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR InhibitorsKavya Ramkumar, C Allison Stewart, Kasey R Cargill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2021
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized StudyLauren Averett Byers, Dmitry Bentsion, Steven Gans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2021
Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung CancerYing Jin, Yamei Chen, Huarong Tang, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 29, 2022
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trialCarminia Maria Della Corte, Morena Fasano, Vincenza Ciaramella, et al.
Molecular Cancer|May 29, 2024
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 studyMingchao Xie, Miljenka Vuko, Jaime Rodriguez-Canales, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2020
Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLCOlsi Gjyshi, Ting Xu, Adnan Elhammali, et al.
Pageof 8